Skip to main content
Print Save

Edarbi Side Effects

Generic name: azilsartan medoxomil

Medically reviewed by Drugs.com. Last updated on Oct 18, 2023.

Note: This document contains side effect information about azilsartan medoxomil. Some dosage forms listed on this page may not apply to the brand name Edarbi.

Applies to azilsartan medoxomil: oral tablet.

Warning

Oral route (Tablet)

Discontinue use of azilsartan medoxomil as quickly as possible if pregnancy is detected as drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

Serious side effects of Edarbi

Along with its needed effects, azilsartan medoxomil (the active ingredient contained in Edarbi) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking azilsartan medoxomil:

Rare

  • Blurred vision
  • confusion
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • sweating
  • unusual tiredness or weakness

Other side effects of Edarbi

Some side effects of azilsartan medoxomil may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Rare

For Healthcare Professionals

Applies to azilsartan medoxomil: oral tablet.

General

The most common side effects were diarrhea, dizziness, headache, dyslipidemia, cough, and increased blood creatine phosphokinase.[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea

Uncommon (0.1% to 1%): Nausea[Ref]

Nervous system

Common (1% to 10%): Dizziness, headache

Frequency not reported: Dizziness postural[Ref]

Metabolic

Common (1% to 10%): Dyslipidemia

Uncommon (0.1% to 1%): Blood uric acid increased, hyperuricemia[Ref]

Respiratory

Common (1% to 10%): Cough[Ref]

Musculoskeletal

Common (1% to 10%): Blood creatine phosphokinase increased

Uncommon (0.1% to 1%): Muscle spasm[Ref]

Dermatologic

Uncommon (0.1% to 1%): Rash, pruritus

Rare (less than 0.1%): Angioedema[Ref]

Other

Uncommon (0.1% to 1%): Fatigue, peripheral edema

Frequency not reported: Asthenia[Ref]

Hematologic

Uncommon (0.1% to 1%): Low hemoglobin, low hematocrit, low RBC counts[Ref]

Renal

Uncommon (0.1% to 1%): Blood creatinine increased[Ref]

Cardiovascular

Uncommon (0.1% to 1%): Hypotension[Ref]

References

1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Product Information. Edarbi (azilsartan). Takeda Pharmaceuticals America. 2011.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer